Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE |
Therapy | Tandutinib |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE | acute myeloid leukemia | sensitive | Tandutinib | Preclinical | Actionable | In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE in culture (PMID: 12124172). | 12124172 |
PubMed Id | Reference Title | Details |
---|---|---|
(12124172) | CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). | Full reference... |